NCT05587478View on ClinicalTrials.gov

A Study of EDP-323 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

September 29, 2022

Primary Completion Date

March 29, 2023

Study Completion Date

March 29, 2023

Conditions
RSV Infection
Interventions
DRUG

EDP-323

Oral administration

DRUG

Placebo

Placebo to match EDP-323, oral administration

Trial Locations (1)

66219

ICON, plc., Lenexa

Sponsors
All Listed Sponsors
lead

Enanta Pharmaceuticals, Inc

INDUSTRY

NCT05587478 - A Study of EDP-323 in Healthy Subjects | Biotech Hunter | Biotech Hunter